De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Mentice Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Mentice heeft een totaal eigen vermogen van SEK152.6M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK310.5M en SEK157.9M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	n/a
Contant	SEK 57.14m
Aandelen	SEK 152.59m
Totaal verplichtingen	SEK 157.92m
Totaal activa	SEK 310.51m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK171.2M ) MN2 } overtreffen de korte termijn passiva ( SEK157.3M ).

Langlopende schulden: De kortetermijnactiva MN2 ( SEK171.2M ) overtreffen de langetermijnschulden ( SEK594.0K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: MN2 is schuldenvrij.

Schuld verminderen: MN2 heeft de afgelopen 5 jaar geen schulden gehad.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende MN2 voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: MN2 is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 43.8 % per jaar groeit.

Mentice Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: kr0.67 (vs kr0.064 in 2Q 2023)

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

New minor risk - Market cap size

New major risk - Share price stability

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.

Director recently bought €71k worth of stock

Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024

Mentice AB (Publ) Announces Board Appointments

Third quarter 2023 earnings released

Mentice AB (publ), Annual General Meeting, May 23, 2024

Mentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024

Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023

New minor risk - Market cap size

Mentice AB (publ) Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)

Insufficient new directors

Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial Officer

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)

Mentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

Mentice AB (publ), Annual General Meeting, May 11, 2023

Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)

Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023

Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.

Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.

First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)

High number of new directors

Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022

High number of new directors

Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business Development

Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Chief Financial Officer Elisabet Lund has left the company

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

Less than half of directors are independent

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)

New 90-day low: €7.52

Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)

Revenue misses expectations

Mentice Announces Executive Appointments

Mentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021

Third quarter 2020 earnings released: kr0.01 loss per share

Revenue misses expectations

Mentice AB (Publ) Announces Nomination Committee

New 90-day low: €7.00

Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.

Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.

Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020

Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high - €7.36

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven